Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,208 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Powder Clear all

Conditions: Infant Development
Interventions: BBN, Brand; Other
Lead sponsor: Building Block Nutritionals, LLC; Industry
Eligibility: 1 Day to 14 Days
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy Aging
Interventions: Nutritional supplement, Placebo; Dietary Supplement
Lead sponsor: Athletic Greens International; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Canfield, Ohio

Conditions: Taste Profile Assessments
Interventions: Tricaprilin; Drug
Lead sponsor: Cerecin; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Woburn, Massachusetts

Conditions: Immune System Diseases
Interventions: HLNatural Immune; Dietary Supplement
Lead sponsor: Hawthorne Effect Inc.; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lafayette, California

Conditions: Sarcopenia
Interventions: XS Muscle Multiplier; Dietary Supplement
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 89 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Asthma
Interventions: Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 9 Years
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 18
States / cities: Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more

Conditions: Asthma
Interventions: Fluticasone propionate, Fluticasone furoate, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 55
States / cities: Birmingham, Alabama • Montgomery, Alabama • Green Valley, Arizona + 45 more

Conditions: Asthma
Interventions: Albuterol Spiromax, ProAir HFA, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 22
States / cities: Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 19 more

Conditions: Asthma
Interventions: CVT-301 (levodopa inhalation powder), Carbidopa, Placebo; Drug · Other
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Daytona Beach, Florida • North Dartmouth, Massachusetts • Dallas, Texas

Conditions: Persistent Asthma
Interventions: Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more

Conditions: COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
Interventions: Aclidinium Bromide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 3,635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 433
States / cities: Birmingham, Alabama • Florence, Alabama • Foley, Alabama + 334 more

Conditions: Epidermolysis Bullosa
Interventions: SD-101-6.0 cream; Drug
Lead sponsor: Scioderm, Inc.; Industry
Eligibility: 1 Month and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 12 more

Conditions: Moderate to Severe Glabellar Lines
Interventions: Corabotase, Placebo; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 41
States / cities: Los Angeles, California • Newport Beach, California • Pasadena, California + 32 more

Conditions: Surgical Wound, Healed
Interventions: CoMatryx Surgical Bovine Collagen; Device
Lead sponsor: MPM Medical; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Healthy
Interventions: HNC042 single dose, Placebo single dose, HNC042 multiple ascending doses, Placebo multiple ascending doses; Drug
Lead sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Locally Advanced Non-Small Cell Lung Cancer, Lung Adenocarcinoma
Interventions: Cromolyn Sodium; Drug
Lead sponsor: Carcinex Inc; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Denver, Colorado

Conditions: Refractory or Unexplained Chronic Cough
Interventions: NOC-110, Placebo; Drug · Other
Lead sponsor: Nocion Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 68
States / cities: Foley, Alabama • Scottsdale, Arizona • Tempe, Arizona + 60 more

Conditions: Gout
Interventions: Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 19
States / cities: Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: LIQ861; Drug
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more

Conditions: Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions: ABI-009, Gemcitabine; Drug
Lead sponsor: Aadi Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: NGLY1 Deficiency
Interventions: GlcNAc-GlcN, Placebo; Drug · Other
Lead sponsor: Eva Morava-Kozicz; Other
Eligibility: 1 Year to 60 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT003 MDI, PT005 MDI, Placebo MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®), Formoterol Fumarate 12 μg (Foradil® Aerolizer®), PT001 MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Clearwater, Florida • Charlotte, North Carolina • Medford, Oregon + 1 more

Conditions: Von Willebrand Diseases
Interventions: Wilate; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 6 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lipomatosis, Multiple Symmetrical
Interventions: Metreleptin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: Up to 60 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Phase II Growth and Safety Study of an Infant Formula for Healthy Term Infants

A Pharmacokinetic Study of a Novel Nutritional Product on Healthy Men and Women

Taste-masking Study for Tricaprilin in Sensory Panelists

Impact of HLNatural Immune Supplement on Colds

Nutritional Biomarkers of Sarcopenia

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients

A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

MPM Medical CoMatryx Surgical Bovine Collagen Study

A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

A Study of GlcNAc on Tear Production in NGLY1-CDDG

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)